The 45 references in paper G. Gorodetskaya I., E. Shikh V., M. Zhuravleva V., S. Serebrova Yu., E. Sokova A., O. Muslimova V., T. Aleksandrova V., I. Mazerkina A., S. Rudnev G., Г. Городецкая И., Е. Ших В., М. Журавлева В., С. Сереброва Ю., Е. Сокова А., О. Муслимова В., Т. Александрова В., И. Мазеркина А., С. Руднев Г. (2018) “Взаимозаменяемость препаратов, содержащих глибенкламид // Interchangeability of glibenclamide-containing drugs” / spz:neicon:vedomostincesmp:y:2017:i:4:p:199-211

1
Scientific substantiation, development and improvement of methodology for assessment of medicinal products interchangeability. Research report (intermediate). FSBI «SCEEMP» of the Ministry of Health of Russia; advisors: Romanov BK, Prokofiev AB, Yagudina RI; prepared by: Alyautdin RN, Zhuravleva MV. Moscow; 2015.
(check this in PDF content)
2
4 p. No. SR 115111740009. Deposited in CITIS on 16.02.2016, No. IKRBS 216021650027 (in Russian). 2. Mashkovsky MD. Medicines. V. 1. Moscow: Meditsina; 1984 (in Russian).
(check this in PDF content)
3
Dedov II, Shestakova MV, Mayorov AYu, Vikulova OK, Galstyan GR, Kuraeva TL, et al. Standards of specialized diabetes care. Diabetes mellitus 2017; 20(1S): 1–112 (in Russian).
(check this in PDF content)
4
Kukes VG, Sychev DA, Andreev DA, Arkhipov VV, Batischeva GA, Berdnikova NG, et al. Ñlinical pharmacology. 5th ed. Moscow: GEOTAR-Media; 2015 (in Russian).
(check this in PDF content)
5
Robertson RP, Porte D. The glucose receptor a defective mechanism in diabetes mellitus distinct from the beta adrenergic receptor. J Clin. Invest. 1973; 52(4): 870–6.
(check this in PDF content)
6
Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988; 37(12): 1595–1607.
(check this in PDF content)
7
Matschinsky F, Liang Y, Kesavan P, Wang L, Froguel P, Velho G, et al. Glucokinase as pancreatic beta cell glucose sensor and diabetes gene. J Clin Invest. 1993; 92(5): 2092–8.
(check this in PDF content)
8
Shestakova MV. Actual clinical practice of treatment of diabetes type 2 in the Russian Federation according to the prospective open observational program «DIA-CONTROL». Diabetes Mellitus 2011; (4): 75–80 (in Russian).
(check this in PDF content)
9
Ashcroft FM, Gribble FM. ATP-sensitive K+channels and insulin secretion: their role in helht and disease. Diabetologia 1999; 42(8): 903–19.
(check this in PDF content)
10
Nedosugova LV, Balabolkin MI. Algorithm treatment diabetes type 2 diabetes. Moscow: MedExpertPress; 2008 (in Russian).
(check this in PDF content)
11
Muller G, Hartz D, Punter J, Okonomopulos R, Kramer W. Differential interaction of glimepiride and glibenclamide with the beta–cell sulfonylurea receptor. I. Binding characteristics. Biochim Biophys Acta 1994; 1191(2): 267–77.
(check this in PDF content)
12
Cozma LS, Luzio SD, Dunseath GJ, Langendorg KW, Pieber T, Owens DR. Comparison of the effects of three insulinotropic drugs on plasma insulin levels after a standard meal. Diabetes Care 2002; 25(8): 1271–6.
(check this in PDF content)
13
Hosker JP, Rudenski AS, Burnett MA, Matthews DR, Turner RC. Similar reduction of first- and second-phaseâ-cell responses at three different glucose levels in type II diabetes and the effect of gliclazide therapy. Metabolism 1989; 38(8): 767–72.
(check this in PDF content)
14
Nikolac N, Simundic AM, Katalinic D, Topic E, Cipak A, Zjacic Rotkvic V. Metabolic control in type 2 diabetes is associated with sulfonylurea receptor-1 (SUR-1) but not with KCNJ11 polymorphisms. Arch Med Res. 2009; 40(5): 387–92.
(check this in PDF content)
15
Holstein A, Hahn M, Stumvoll M, Kovacs P. The E23K variant of KCNJ11 and the risk for severe sulfonylurea-induced hypoglycemia in patients with type 2 diabetes. Horm Metab Res. 2009; 41(5): 387–90.
(check this in PDF content)
16
Balabolkin MI, Kreminskaya VM, Klebanova EM. Modern tactics of treatment of diabetes mellitus type 2. Consilium medicum 2001; 3(11): 535–40 (in Russian).
(check this in PDF content)
17
Nyomba BL, Freymond D, Raz I, Stone K, Mott DM, Bogardus C. Skeletal muscle glycogen synthase activity in subjects with non-insulin-dependent diabetes mellitus after glyburide therapy. Metab Clin Exp. 1990; 39(3): 1204–10.
(check this in PDF content)
18
Fronzo RA, Simonson DC. Oral sulfonylurea agents suppress hepatic glucose production in non-insulin-dependent diabetic individuals. Diabetes Care 1984; 7(1): 72–80.
(check this in PDF content)
19
Klepzig H, Kober G, Matter C, Luus H, Schneider H, Boedeker KH, et al. Sulfonylureas and ischemic preconditioning. A double-blind, placebo-controlled evolution of glimepiride and glibenclamide. Eur Heart J. 1999; 20(6): 439–46.
(check this in PDF content)
20
Bartsch SE, Abberger T, Griesser UJ. Melt granulation of solid dispersions — granulation mechanism, tableting and dissolution behavior. Abstr. 17th Congress of the Austrian Pharmaceutical Society. Graz, 24–26 April, 2003.
(check this in PDF content)
21
Wei H, Lobenberg R. Biorelevant dissolution media as a predictive tool for glyburide a class II drug. Eur J Pharm Sci. 2006; 29(1): 45–52.
(check this in PDF content)
22
Karpov OI. Micronized glibenclamide — a modification of the dosage form and kinetics aimed at the result. Russian medical journal 2006; (26): 1940–3 (in Russian).
(check this in PDF content)
23
Glyburide Micronized Description. Available from: https://www.drugs.com/ pro/glyburide-micronized.html.
(check this in PDF content)
24
Christ OE, Heptner W, Rupp W. Investigations on absorption, excretion and metabolism in man after administration of14C-labelled HB 419. Horm Metab Res. 1969; 1 (Suppl. l): 51–4.
(check this in PDF content)
25
Gorodetsky VV, Gorodetskaya GI, Shikh EV, Zhukovskaya AV. Can we cause a drug induction of izoenzymes of cytochrome P450, metabolizing sulfonylureas in patients with type 2 diabetes mellitus with polymorphism of genes, encoding these izoensymes? Medicines and rational pharmacotherapy 2013; (2): 20–6 (in Russian). Available from: http:// macff.ru/images/arhiv/2013-2.pdf.
(check this in PDF content)
26
Surendiran A, Pradhan SC, Agraval A, Subrahmanyam DK, Rajan S, Anichavezhi D, et al. Influence of CYP2C9 gene polymorphism on response to glibenclamide in type 2 diabetes mellitus patients. Eur J Clin Pharmacol. 2011; 67(8): 797–801.
(check this in PDF content)
27
Rudakova IP, Ilyina IG, Skachilova SYa, Melentieva TA, Mikhalev OV, Samylina IA. Polymorphism and properties of drugs. Pharmacy 2009; (8): 42–4 (in Russian).
(check this in PDF content)
28
Zilov AV, Morgunova TB, Terekhova AL. The frequency of hypoglycemia and cardiovascular disorders in patients treated with sulfonylureas compared with other secretagogues: a systematic review. Diabetes Mellitus 2010; (2): 85–90 (in Russian).
(check this in PDF content)
29
Carlson RF, Isley WL, Ogrinc FG, Klobucar TR. Efficacy and safety of reformulated, micronized glyburide tablets in patients with non-insulin-dependent diabetes mellitus: a multicenter, double-blind, randomized trial. Clin Ther. 1993; 15(5): 788–96.
(check this in PDF content)
30
State register of medicines. Available from: https://grls.rosminzdrav.ru (in Russian).
(check this in PDF content)
31
Antsiferov MB, Mayorov AYu. Use of combined oral glucose reducing drug Glibomet in the treatment of patients with type 2 diabetes mellitus. Moscow: Berlin-Chemie/Menarini Group; 2001 (in Russian).
(check this in PDF content)
32
Ametov AS. Diabetes mellitus type 2. Problems and solutions. Moscow: GEOTAR-Media; 2012 (in Russian).
(check this in PDF content)
33
Donahue SR, Turner KC, Patel S. Pharmacokinetics and pharmacodynamics of glyburide/metformin tablets (Glucovance) versus equivalent doses of glyburide and metformin in patients with type 2 diabetes. Clin Pharmacokinet. 2002; 41(15): 1301–9.
(check this in PDF content)
34
Nikonova TB. Modern algorithm for the treatment of type 2 diabetes mellitus. To whom and how to prescribe combined hypoglycemic preparations. Consilium medicum 2008; 10(9): 25–9 (in Russian).
(check this in PDF content)
35
Eadala P, Waud JP, Matthews SB, Green JT, Campell AK. Quantifying the «hidden» lactose in drugs used for the treatment of gastrointestinal conditions. Aliment Pharmacol Ther. 2009; 29(6): 677–87.
(check this in PDF content)
36
Trofimov SV. High molecular cellulose esters. Mechanism of action in sustained release matrix tablets. Dissolution profile of active drug depending on molecular weight and hydrophilic properties of polymers. Pharmacy & Pharmacology 2015; 3(5): 18–25 (in Russian).
(check this in PDF content)
37
Mogilyuk V. Lubricants for solid dosage forms: Compritol 888 ATO and Precirol ATO 5. Pharmaceutical industry 2010; (6): 60–3 (in Russian).
(check this in PDF content)
38
Suleiman MS, Najib NM. Isolation and physicochemical characterization of solid forms of glibenclamide. Int J Pharm.1989; 50(2): 103–9.
(check this in PDF content)
39
Yalkowsky SH, He Y. Handbook of aqueous solubility data. New York: CRC Press; 2003.
(check this in PDF content)
40
Trofimov SV, Stepanova EF. Medicinal forms of glibenclamide: modern technologies for an actual problems’ solution. Development and registration of medicines 2014; (7): 64–7 (in Russian).
(check this in PDF content)
41
ApprovedDrug Products with Therapeutic Equivalence Evaluations. 37th edition. 2017. Available from: https:// goo.gl/LAUEC2.
(check this in PDF content)
42
Romanov BK, Sakaeva IV, Bunyatyan ND, Vasiliev AN, Bondarev VP, Prokofiev AB, et al. The algorithm of evaluation of interchangeability of pharmaceuticals. Medical Journal of the Russian Federation 2015; (5): 43–6 (in Russian).
(check this in PDF content)
43
Bukatina TM, Kazakov AS, Velts NYu, Darmostukova MA, Zatolochina KE, Alyautdin RN, et al. Ketoacidosis as unexpected adverse reaction SGLT2inhibitor. Safety and Risk of Pharmacotherapy 2016; (4): 22–5 (in Russian).
(check this in PDF content)
44
Chuchalin AG, Hohlov AL, eds. Federal guidance on the use of drugs (formulary system). Issue XVIII. Moscow: Vidoks; 2017 (in Russian).
(check this in PDF content)
45
Scientific substantiation, development and improvement of methodology for assessment of medicinal products interchangeability. Research report (intermediate). FSBI «SCEEMP» of the Ministry of Health of Russia; advisors: Romanov BK, Prokofiev AB, Yagudina RI; prepared by: Alyautdin RN, Zhuravleva MV. Moscow; 2016. 365 p.
(check this in PDF content)